Navigation Links
Innova 4200 Benchtop or Floor-Stackable Incubator Shaker, 1.00" Orbit
Performa uncemented stem.
Porous foundation 480 series.
The Opteon stem meets the challenge of providing a high-quality, cost-effective hip implant for the moderate demand patient.
Exactech's AcuMatch C-Series (cemented femoral stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty.
Medicine Products:
(Date:12/4/2008)...4 Two researchers who translate ma...used on stopping breast cancer in its,tracks are ... Scientific,Distinction in basic research and cli...an Antonio, Susan G. Komen for the Cure(R) announc.../cgi-bin/prnh/20070122/NYM084LOGO ) , Award...
(Date:12/4/2008)...ec. 4 The U.S. Governme...lopment (USAID), is providing an additional $600,0.... This assistance is in addition to the $4 millio... USAID is already implementing in Zimbabwe. , ...king alongside the international community to prep...
(Date:12/4/2008)...ecember 4, 2008) - An Ontario study of 491 women ...oportion, 19%, were referred for genetic testing o...means family members are not informed of their can...ofessor at the University of Toronto,s Lawrence S....ntist at Women,s College Research Institute, led t...
(Date:12/4/2008)...ll., Dec. 4 NAMC members can gain ...your desktop. Webinars feature nationally-recogniz...computer. The next webinar will be on December 10...Online Audience , Do you know where your online... them, do you know how to engage them? , This ...
Breaking Medicine News(10 mins):Health News:Susan G. Komen for the Cure(R) Announces Recipients of 2008 Komen Brinker Award for Scientific Distinction 2Health News:USAID Increases Assistance for Zimbabwe Cholera Outbreak 2Health News:Few Ontario women with invasive ovarian cancer referred for genetic testing of breast cancer genes 2Health News:New NAMC Member Service! Complimentary Webinars for NAMC Members - On Topics You Need to Know! Sign Up Today for This New and Exciting Educational Program! 2
...th authorities in Romania have confirmed the prese...ction of the bird flu infection in Ostrov // (near...irmed to be affected by bird flu. Laboratory exam...oultry has been confirmed to be positive for bird ...
...w study said that complex regional pain syndrome i...ve injury affecting small fibers which has the abi...the post-traumatic limb pain and other disturbance...e injury has healed. But the causes of the symptom...
...dian-led researchers say that they have formulated...in in infants. It was believed for a long time tha...eory has been laid to rest by stringent research. ...thout affecting the basic constitution of infants....
... takers are at a lesser risk of Parkinson’s, accor...f Neurology Neurosurgery and Psychiatry. // The r...sons between 106 Parkinson’s patients and 106 heal...and sex. The groups’ responded to questions that s...
Other Medicine News:
(Date:12/3/2008)... Roche today announced that the U.... further guidance on the requirements for the Biol...cilizumab), the first interleukin-6 (IL-6) recepto...reatment of adult patients with moderately to seve... As a result of the FDA,s evolving Risk Evaluation...
(Date:12/3/2008)...ec. 3 Wyeth Pharmaceutic...d today that it has submitted a,marketing authori... Agency,(EMEA) for approval to market its investi... (PCV13) for infants and young children. Wyeth is...mococcal disease (PD) caused by the 13,serotypes ...
(Date:12/3/2008)...RNewswire-FirstCall/ -- Vical Incorporated,(Nasda...letter of intent with EIP,Eczacibasi Ilac Pazarla...ny,s,Allovectin-7(R) immunotherapeutic product ca...thern Cyprus. EIP has agreed to obtain the necessa...pay Vical upfront and milestone payments,plus a s...
(Date:12/2/2008)... IBT Laboratories, a leading clin...y specializing in immunology and allergy assays, a...te the response of patients whose immune systems ...cy disorder, chemotherapy drugs, or because they a...ction of a transplant. The company launched the tw...
Breaking Medicine Technology:Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 2Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 3Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 4Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 5Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5IBT Laboratories Expands its Menu of Tests for Immune Deficiency 2Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results 965 1Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results 965 2Annals of Internal Medicine tip sheet for Oct 2 2524 1Annals of Internal Medicine tip sheet for Oct 2 2524 2Leaders in addiction treatment announce national ACTION campaign 2521 1Leaders in addiction treatment announce national ACTION campaign 2521 2Hologic Chairman and CEO to Open NASDAQ Stock Market on October 2 2007 2518 1Hologic Chairman and CEO to Open NASDAQ Stock Market on October 2 2007 2518 2Hologic Chairman and CEO to Open NASDAQ Stock Market on October 2 2007 2518 3Hologic Chairman and CEO to Open NASDAQ Stock Market on October 2 2007 2518 4
...– June 25 – MediQuest Therapeutics,In...developing,therapies for inflammatory and infectio... confirmatory phase III study of Vascana,– a...uo;s,Disease. , The study met its primary end poin...p = 0.008 for the Intent-to-Treat patient,populati...
...otechnology Company updates progress and upcoming,... 26, 2007 /PRNewswire-FirstCall/ - SemBioSys,Genet...rtfolio of,therapeutic proteins for metabolic and ...reclinical data supporting the,development of plan...resented its findings at the 67th Scientific Sessi...
Other Medicine Technology:MediQuest Concludes Confirmatory Phase III Study of Raynaud’s,Therapy 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 3SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 4